Type 2 diabetes
Conditions
Interventions
Glycemic levels were monitored for 7 consecutive days using CGM (ipro2
Medtronic MiniMed Inc., Northridge, CA).During the study period, the dose ofinsulin and other antidiabetic drugs were fixed.The patients were divided three arms. After starting glucose monitoring,
Sponsors
Dokkyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Type 2 diabetes in patient 2)Postprandial glucose levels > 180mg/dl 3)HbA1c values at admition between 7.0 and 13.5% 4)Patients who gave written informed consent
Exclusion criteria
Exclusion criteria: 1)Patients who have severe diabeticketosis, diabetic coma 2)Patients with severe infections, severe injury or perioperative state. 3)Female patients who have pregnancy or possibilty of pregnancy, or are under lactation 4)Patients who had past history of hypersensitivity or allergic reaction to insulin degludec, aspart or liraglutide 5)Patients with severe liver or renal dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total area under the curve (AUC) within 2 h after each meal, and postprandial glucose levels within 2 h after each meals using 24-h glycemic data from CGM | — |
Secondary
| Measure | Time frame |
|---|---|
| we evaluated 24-h mean glucose levels,the mean of the daily difference, mean amplitude of glycemic excursions,rates of proportions of appropriate glucose levels, hyperglycemia, andhypoglycemia | — |
Countries
Japan
Contacts
Public ContactTakafumi Niitani
Dokkyo Medical University Endocrinology and Metabolism
Outcome results
None listed